Recent Posts
- MM1YA-CTG01: A measurable residual disease (MRD) focused, phase II study of venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk Acute Myeloid Leukemia (AML): A Tier 1 myeloMATCH Clinical Trial
- MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial (NCT06317649)
- MYELOMATCH: Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials (NCT # 05564390)
- S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- MMCORC 2023/2024 Highlights
Recent Comments
No comments to show.